Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 6/20 | 0.54 |
| ▸ | DRD5 | P21918 | 5/20 | 0.54 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 4/20 | 0.53 |
| ▸ | DRD3 | P35462 | 4/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.49 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | METAP1 | P53582 | 1/20 | 0.47 |
| ▸ | BCL2 | P10415 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | MPO | P05164 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26767768 | 1.00 | DRD1 (0.54) | DRD1DRD5RYR2DRD2DRD3 | |
| SCHEMBL4310710 | 0.88 | L3MBTL1 (0.49) | DRD1DRD5RYR2DRD2DRD3 | |
| SCHEMBL3902560 | 0.86 | DRD1 (0.65) | DRD1DRD5RYR2DRD2DRD3 | |
| SCHEMBL26768689 | 0.79 | METAP1 (0.44) | DRD1DRD5RYR2DRD2DRD3 | |
| SCHEMBL30777630 | 0.79 | METAP1 (0.63) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL17108416 | 0.79 | MPO (0.59) | METAP1BCL2MPOKDM4E | |
| SCHEMBL4581239 | 0.79 | METAP1 (0.63) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL8222715 | 0.78 | METAP1 (0.50) | DRD1DRD5DRD2DRD3METAP1 | |
| SCHEMBL30021259 | 0.78 | METAP1 (0.50) | DRD1DRD5DRD2DRD3METAP1 | |
| SCHEMBL29853715 | 0.78 | METAP1 (0.46) | DRD1DRD5DRD2DRD3METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712958-A2 | USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Vandria SA (CH) | 2026-03-25 | — | — | EP | disclosed |
| EP-4561556-A2 | THERAPEUTIC USES OF UROLITHIN DERIVATIVES | Vandria SA (CH) | 2025-06-04 | — | — | EP | disclosed |
| CN-119947717-A | Therapeutic use of urolithin derivatives | 范徳利亚股份公司 | 2025-05-06 | — | — | CN | disclosed |
| WO-2024236367-A2 | USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | VANDRIA SA (CH) | 2024-11-21 | — | — | WO | disclosed |
| WO-2024025953-A2 | THERAPEUTIC USES OF UROLITHIN DERIVATIVES | VANDRIA SA (CH) | 2024-02-01 | — | — | WO | disclosed |
| EP-4284781-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | Vandria SA (CH) | 2023-12-06 | — | — | EP | disclosed |
| CN-117015530-A | Urolithin derivatives and methods of use thereof | 范徳利亚股份公司 | 2023-11-07 | — | — | CN | disclosed |
| WO-2022162471-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | VANDRIA SA (CH) | 2022-08-04 | — | — | WO | disclosed |